Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentary

Fatty Acids and Insulin Secretion: From FFAR and Near?

  1. Vincent Poitout⇑
  1. Centre de Recherche du Centre hospitalier de l'Université de Montréal, Montreal Diabetes Research Center, and Department of Medicine, University of Montreal, Montreal, Canada
  1. Corresponding author: Vincent Poitout, vincent.poitout{at}umontreal.ca.
Diabetes 2018 Oct; 67(10): 1932-1934. https://doi.org/10.2337/dbi18-0027
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Nonesterified, long-chain fatty acids (LCFAs) potentiate glucose-stimulated insulin secretion (GSIS). In other words, LCFAs do not trigger insulin release by themselves but strongly amplify the stimulating effect of glucose (1). Yet, from a physiological standpoint it does not seem logical that an energetic substrate whose circulating levels are elevated when glucose levels are low would stimulate insulin release (2). This apparent contradiction can be resolved if the LCFAs that stimulate insulin secretion come from the local islet environment, where their concentrations are likely significantly higher than plasma levels, rather than from the circulation (3).

LCFA potentiation of GSIS occurs via at least two distinct mechanisms. LCFAs are transported across the plasma membrane, activated into long-chain acyl-CoA, and metabolized to generate lipid signaling molecules that promote insulin exocytosis when glucose levels are elevated (3). LCFAs also bind to and activate the G-protein–coupled receptor FFAR1 (GPR40), which is mainly coupled to Gαq/11 and triggers a signaling cascade leading to the activation of protein kinase D1 and insulin release (4) (Fig. 1). Intracellular metabolism and FFAR1 activation each account for approximately 50% of the overall effect of exogenous LCFA on insulin release (5). The question of how much LCFA is available at the vicinity of the islet for uptake or FFAR1 activation is complex. First, the vast majority of LCFA in the circulation and interstitial space is bound to albumin, and the bioactive, non-BSA–bound fraction is extremely small (6). Second, lipoprotein lipase expressed in islet capillaries delivers LCFA from postprandial chylomicrons to the β-cell (7). Third, β-cells exhibit significant glucose-stimulated lipolytic activity (8,9), which results in LCFA release in the extracellular space (10). This later observation suggests a possible autocrine effect of LCFA on insulin secretion (2,3).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

A potential feed-forward autocrine signaling loop involving FFAR1 to regulate GSIS. The primary signal for insulin secretion is glucose metabolism. Glucose enters the cell through its transporter Glut2. Glucose metabolism leads to an increase in the ATP/ADP ratio, closure of the ATP-sensitive potassium (KATP) channel, Ca2+ influx through the voltage-dependent calcium channel (VDCC), and insulin secretion. The concentration of LCFAs at the vicinity of the β-cell after a meal is predominantly determined by the local activity of lipoprotein lipase (LPL) releasing LCFA from chylomicrons (7) and by glucose-stimulated lipolysis and release of LCFA from β-cell triglycerides (TG) and phospholipids (PL) (8–10). LCFAs can then either be transported into the β-cell across the plasma membrane or bind to their receptor FFAR1. Intracellular LCFAs are activated into long-chain acyl-CoA (LC-CoA), which can directly modulate ion channel activity (23,24). LCFA binding to FFAR1 triggers Gαq/11-mediated activation of phospholipase C (PLC) and generation of inositol-3-phosphate (IP3) and diacylglycerol (DAG). IP3 binds to its receptor (IP3R) and promotes Ca2+ efflux from the endoplasmic reticulum. DAG activates protein kinase D1 (PKD1), which enhances insulin secretion through F-actin remodeling, and protein kinase C (PKC) isoforms, which contribute to the increase in intracellular Ca2+ (25). In addition, glucose promotes the formation of 20-HETE from arachidonic acid. 20-HETE is released from the cell and binds to FFAR1 (20).

In this issue of Diabetes, Hauke et al. (11) used complementary approaches to examine the role of endogenous LCFA on insulin secretion in insulin-secreting MIN6 cells and mouse primary β-cells. First, the authors showed that stringent washing in a perifusion system decreased cytosolic Ca2+ oscillations in response to glucose, which were recovered by addition of preconditioned medium from MIN6 cells. Second, addition of fatty acid (FA)–free BSA to the incubation buffer also impaired glucose-induced Ca2+oscillations and insulin secretion, an effect that was not observed if the BSA was preloaded with LCFA or chemicals that occupy the LCFA binding sites. The recovery of Ca2+ oscillations and insulin secretion was prevented in the presence of the FFAR1 inhibitor GW1100. Mass spectrometry analyses confirmed the predominance of palmitic and stearic acids in both cell extracts and supernatants. Next, the authors used sulfo-caged stearic and oleic acid with a photo-labile caging group (12) to deliver LCFAs at the plasma membrane. Ultraviolet-mediated release of LCFA led to recovery of Ca2+ oscillations in cells previously depleted by FA-free BSA incubation. Accordingly, forced stimulation of LCFA release by recombinant phospholipase A2 or lipoprotein lipase also restored Ca2+ oscillations and insulin secretion. Overall, the authors concluded that endogenous LCFAs contribute to the normal regulation of GSIS and that provision of exogenous LCFAs restores GSIS through FFAR1 signaling.

These findings, using thorough and complementary approaches, elegantly corroborate the notion that endogenous LCFA signaling plays a key role in stimulus-secretion coupling in the β-cell. The results also strongly suggest, but do not formally prove, that LCFAs released by the β-cell signal back on the same or neighboring cells in an autocrine or paracrine manner (Fig. 1). The data using the FFAR1 inhibitor indicate that this may be the case but would benefit from additional confirmation in islets from FFAR1 knockout animals. In fact, the extent to which FFAR1 signaling is involved in the observed effects is not entirely clear. Hauke et al. (11) suggest that the rapid termination and fast recovery of β-cell activity upon addition and reprovision of FA-free BSA is due to direct action of LCFA on ion channel activity, whereas FFAR1 signaling is implicated in longer-term effects. Yet, as discussed by the authors, FFAR1 signaling has also been shown to modulate ion channel activity in β-cells (13–17).

Of note, the reduction of β-cell activity upon washing with FA-free BSA is in contradiction with an earlier report by Straub and Sharp (18), who observed a large increase in insulin secretion from rat islets following a 4- to 6-h preincubation with FA-free BSA, a discrepancy that may be explained by the different time frames of the two studies (19).

A precedent for an autocrine action of lipid derivatives in β-cells was recently established by Tunaru et al. (20), who showed that the eicosanoid metabolite of arachidonic acid, 20-hydroxyeicosatetraenoic acid (20-HETE), is released in response to glucose, binds to FFAR1, and promotes GSIS (Fig. 1). The notion that LCFAs or derivatives “secreted” by the β-cell in response to glucose signal through FFAR1 to potentiate GSIS does resolve the physiological contradiction mentioned above and is consistent with the fact that the circulating concentration of non-BSA–bound LCFA is likely lower that of the EC50 for FFAR1 (2). However, if this glucose-induced, feed-forward autocrine signaling loop is essential for GSIS, one would expect FFAR1 knockout mouse islets to exhibit lower GSIS, which is not consistently observed (5,20). This issue is intrinsically difficult to assess experimentally as any manipulation of intracellular LCFA levels to limit their release will also alter the generation of intracellular signaling molecules that contribute to GSIS (3).

In summary, the study by Hauke et al. (11) confirms the critical role of endogenous LCFA signaling in the control of GSIS and presents converging and convincing lines of evidence in support of LCFA being added to the list of molecules to contribute to autocrine regulation of β-cell function (reviewed in ref. 21). It remains to be determined whether such a mechanism is operative and functionally important in human islets. Interestingly, both FFAR1 expression (22) and glucose-induced 20-HETE formation (20) are reduced in islets from subjects with type 2 diabetes, suggesting the possibility that this autocrine feedback loop may indeed contribute to islet dysfunction in type 2 diabetes.

Article Information

Funding. Work from V.P.’s laboratory was supported by the Canadian Institutes of Health Research (MOP 86545 to V.P.). V.P. holds the Canada Research Chair in Diabetes and Pancreatic β-Cell Function.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 1986.

  • © 2018 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Crespin SR,
    2. Greenough WB III.,
    3. Steinberg D
    . Stimulation of insulin secretion by infusion of free fatty acids. J Clin Invest 1969;48:1934–1943pmid:5822597
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Husted AS,
    2. Trauelsen M,
    3. Rudenko O,
    4. Hjorth SA,
    5. Schwartz TW
    . GPCR-mediated signaling of metabolites. Cell Metab 2017;25:777–796pmid:28380372
    OpenUrlCrossRefPubMed
  3. ↵
    1. Nolan CJ,
    2. Madiraju MS,
    3. Delghingaro-Augusto V,
    4. Peyot ML,
    5. Prentki M
    . Fatty acid signaling in the β-cell and insulin secretion. Diabetes 2006;55(Suppl. 2):S16–S23pmid:17130640
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Ferdaoussi M,
    2. Bergeron V,
    3. Zarrouki B, et al
    . G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 2012;55:2682–2692pmid:22820510
    OpenUrlCrossRefPubMed
  5. ↵
    1. Latour MG,
    2. Alquier T,
    3. Oseid E, et al
    . GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007;56:1087–1094pmid:17395749
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontés G. Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 2010;1801:289–298
  7. ↵
    1. Cruz WS,
    2. Kwon G,
    3. Marshall CA,
    4. McDaniel ML,
    5. Semenkovich CF
    . Glucose and insulin stimulate heparin-releasable lipoprotein lipase activity in mouse islets and INS-1 cells. A potential link between insulin resistance and beta-cell dysfunction. J Biol Chem 2001;276:12162–12168pmid:11154699
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Peyot M-L,
    2. Nolan CJ,
    3. Soni K, et al
    . Hormone-sensitive lipase has a role in lipid signaling for insulin secretion but is nonessential for the incretin action of glucagon-like peptide 1. Diabetes 2004;53:1733–1742pmid:15220197
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Mulder H,
    2. Yang S,
    3. Winzell MS,
    4. Holm C,
    5. Ahrén B
    . Inhibition of lipase activity and lipolysis in rat islets reduces insulin secretion. Diabetes 2004;53:122–128pmid:14693706
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Mugabo Y,
    2. Zhao S,
    3. Lamontagne J, et al
    . Metabolic fate of glucose and candidate signaling and excess-fuel detoxification pathways in pancreatic β-cells. J Biol Chem 2017;292:7407–7422pmid:28280244
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Hauke S,
    2. Keutler K,
    3. Phapale P,
    4. Yushchenko DA,
    5. Schultz C
    . Endogenous fatty acids are essential signaling factors of pancreatic β-cells and insulin secretion. Diabetes 2018;67:1986–1998pmid:29748290
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Nadler A,
    2. Yushchenko DA,
    3. Müller R, et al
    . Exclusive photorelease of signalling lipids at the plasma membrane. Nat Commun 2015;6:10056pmid:26686736
    OpenUrlPubMed
  13. ↵
    1. Yamada H,
    2. Yoshida M,
    3. Ito K, et al
    . Potentiation of glucose-stimulated insulin secretion by the GPR40-PLC-TRPC pathway in pancreatic β-cells. Sci Rep 2016;6:25912pmid:27180622
    OpenUrlCrossRefPubMed
    1. Schnell S,
    2. Schaefer M,
    3. Schöfl C
    . Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol Cell Endocrinol 2007;263:173–180pmid:17101212
    OpenUrlCrossRefPubMedWeb of Science
    1. Shapiro H,
    2. Shachar S,
    3. Sekler I,
    4. Hershfinkel M,
    5. Walker MD
    . Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun 2005;335:97–104pmid:16081037
    OpenUrlCrossRefPubMedWeb of Science
    1. Feng DD,
    2. Luo Z,
    3. Roh SG, et al
    . Reduction in voltage-gated K+ currents in primary cultured rat pancreatic beta-cells by linoleic acids. Endocrinology 2006;147:674–682pmid:16254037
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Frank JA,
    2. Yushchenko DA,
    3. Fine NHF, et al
    . Optical control of GPR40 signalling in pancreatic β-cells. Chem Sci (Camb) 2017;8:7604–7610pmid:29568424
    OpenUrlPubMed
  15. ↵
    1. Straub SG,
    2. Sharp GW
    . Massive augmentation of stimulated insulin secretion induced by fatty acid-free BSA in rat pancreatic islets. Diabetes 2004;53:3152–3158pmid:15561945
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Alsabeeh N, Chausse B, Kakimoto PA, Kowaltowski AJ, Shirihai O. Cell culture models of fatty acid overload: problems and solutions. Biochim Biophys Acta 2018;1863:143–151
  17. ↵
    1. Tunaru S,
    2. Bonnavion R,
    3. Brandenburger I, et al
    . 20-HETE promotes glucose-stimulated insulin secretion in an autocrine manner through FFAR1. Nat Commun 2018;9:177pmid:29330456
    OpenUrlPubMed
  18. ↵
    1. Braun M,
    2. Ramracheya R,
    3. Rorsman P
    . Autocrine regulation of insulin secretion. Diabetes Obes Metab 2012;14(Suppl. 3):143–151pmid:22928575
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Del Guerra S,
    2. Bugliani M,
    3. D’Aleo V, et al
    . G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutr Metab Cardiovasc Dis 2010;20:22–25pmid:19758793
    OpenUrlCrossRefPubMed
  20. ↵
    1. Larsson O,
    2. Deeney JT,
    3. Bränström R,
    4. Berggren P-O,
    5. Corkey BE
    . Activation of the ATP-sensitive K+ channel by long chain acyl-CoA. A role in modulation of pancreatic β-cell glucose sensitivity. J Biol Chem 1996;271:10623–10626pmid:8631866
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Gribble FM,
    2. Proks P,
    3. Corkey BE,
    4. Ashcroft FM
    . Mechanism of cloned ATP-sensitive potassium channel activation by oleoyl-CoA. J Biol Chem 1998;273:26383–26387pmid:9756869
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Mancini AD,
    2. Poitout V
    . The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol Metab 2013;24:398–407pmid:23631851
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes: 67 (10)

In this Issue

October 2018, 67(10)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fatty Acids and Insulin Secretion: From FFAR and Near?
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Fatty Acids and Insulin Secretion: From FFAR and Near?
Vincent Poitout
Diabetes Oct 2018, 67 (10) 1932-1934; DOI: 10.2337/dbi18-0027

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Fatty Acids and Insulin Secretion: From FFAR and Near?
Vincent Poitout
Diabetes Oct 2018, 67 (10) 1932-1934; DOI: 10.2337/dbi18-0027
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Lifting the Veil on the “Phosphate Flush,” a Cryptic Phenomenon of Experimental Pancreatic Islet Physiology
  • Window of Opportunity: Targeting ANGPTL4 Improves Triglyceride Levels in Maternal Obesity During Pregnancy
  • New Antidiabetes Agent Targeting Both Mitochondrial Uncoupling and Pyruvate Catabolism: Two Birds With One Stone
Show more Commentary

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.